Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Børge Nordestgaard MD, DMSc

Børge G. Nordestgaard MD, DMSc

Professor, University of Copenhagen, Chief Physician, Dept. Clinical Biochemistry, Herlev and Gentofte Hospital, Copenhagen University Hospital, Herlev, Denmark

Prof. Nordestgaard studied and worked in Copenhagen, New York, and London.

Prof. Nordestgaard has for more than 30 years continued his interest in the pathogenesis, diagnosis and treatment of familial hypercholesterolemia, hyperlipidemia, atherosclerosis, diabetes and cardiovascular disease, and has written extensively on these conditions.

He is chairing the Copenhagen General Population Study and is also a steering committee member of the Copenhagen City Heart Study and of four phase 3 endpoint cardiovascular randomised intervention trials.

Prof. Nordestgaard has supervised 71 PhD students and 34 postdoctoral fellows, and has published 886 original articles and 136 reviews, book chapters, consensus statements, & editorials. His H-index is 145 in Web of Science and he is listed among the 7000 researchers World-wide with the most highly cited papers.

Original articles include publications in New England Journal of Medicine, Lancet, Journal of the American Medical Association, Nature, Science, Nature Genetics, British Medical Journal, Lancet Diabetes Endocrinology, Circulation, European Heart Journal, Journal of the American College of Cardiology and JAMA cardiology.


Conflict of Interest Disclosure: the Danish taxpayer and consultancies/talks for AstraZeneca, Sanofi, Regeneron, Ionis, Amgen, Kowa, Denka, Amarin, Novartis, Novo Nordisk, Esperion, Abbott, Silence Therapeutics.